NeuClone is a biotech company specializing in cell line engineering for the biopharmaceutical and biomanufacturing industries.

NeuClone has developed a platform technology for the commercial production of protein therapeutics. The platform consists of :

1) a proprietary Chinese hamster ovary (CHO) cell line with superior growth properties and production capabilities, named NeuCHO,

2) DNA expression vectors designed for high-level expression of single chain proteins and monoclonal antibodies (Mabs), and

3) a growing portfolio of engineered cell lines that are expressing biosimilars.

NeuClone's cell lines secreting various biosimilars are available for licensing.